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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground: Human cytomegalovirus (HCMV) can cause acute or chronic diseases, especially in
immunocompromised patients. Currently, most drugs licensed for the treatment of the herpes
virus are nucleoside analogs that have been developed over the past 25 years. Drug resistance,
development of drug related toxicity, and side effects limit their clinical use in patients. In a
previous study, we found a trapping ligand H22-LP (the conservative sequence is NAHCALL)
from a random phage library according to the broad-spectrum trapping receptor H22, which
derived from the residue 14-35 near the N-terminal region of receptor US28 on HCMV. Here,
the aim was to evaluate the anti-HCMV activity of H22-LP.
Methods: Antivirus activity of H22-LP on HCMV replication was visualized by fluorescence mi-
croscopy. We determined the effects of H22-LP on the expressions of HCMV late protein using
q-PCR and Western blot. Comprehensive analysis of the characteristics of H22LP-mediated in-
hibition of HCMV were quantitatively analyzed by flow cytometry.
Results: H22-LP showed a 65.4% inhibition of viral infection at a concentration of 10 ng, and
50% inhibition at concentrations of 5 ng. The levels of mRNA and proteins were also found
to have decreased by H22-LP in a concentration-dependent manner. The mode of antiviral ac-
tion is based on a block of viral entry cells during HCMV cell adsorption/entry.
Conclusion: These results demonstrated that H22-LP could inhibit HCMV by direct interaction
with the viral particle.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Genomic Medicine, College of Pharmacy, Jinan University, 601 Huangpu Street, Tianhe District,
il.com (H. Sun).
.06.010
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Human cytomegalovirus (HCMV) is a ubiquitous, world-
wide virus with a high clinical relevance. Infection with
the virus can cause mild to severe diseases, especially in
immunocompromised patients.1 Herpes simplex virus
fuses directly with the plasma membrane. During its life
cycle, HCMV is first adsorbed in the cell membrane. After
penetration of the adsorbed virus, the incoming nucleo-
capsids are transported to the nuclear pore where the
DNA is released into the nucleus. Herpes viruses are
dependent on the host cytoskeleton for efficient entry,
replication, and egress. Herpes viruses have developed a
variety of strategies [e.g., members of the herpes viruses
encode Viral G-protein-coupled receptors (vGPCRs)] to
evade the immune system, which refers to the commu-
nication between numerous virus genes and cells. vGPCRs
that show homology to human chemokine receptors make
significant contributions to the viral lifecycle and associ-
ated pathologies.2 During infection, viral entry cells play a
key role in viral spread. US28 encoded by HCMV is the best
characterized 7TM/GPCR and is suggested to enhance cell
to cell fusion. US28 apparently shares properties with the
cellular chemokine receptors CCR5 and CXCR4, which
behave as CD4-associated coreceptors for human immu-
nodeficiency virus (HIV)-1 or HIV-2.3,4 US28 can form
multiple signaling pathways to activate the immediate
early HCMV promoter, which generally leads to the regu-
lation of transcription factors such as nuclear factor kB
(NFkB).5,6
DNA polymerase has been extensively studied as a
target for antiviral drugs. Currently, several drugs such as
ganciclovir (GCV) and cidofovir (CDV) have been tested
for their ability to inhibit herpes viruses with normal
molecular mechanisms in vitro.7,8 However, such antiviral
therapy of HCMV-associated diseases is generally
complicated by a number of clinical problems, such as
drug resistance, development of drug related toxicity,
and side effects.1,9 A recent review focused on the tar-
gets, used or under investigation, for the treatment of
HCMV infections.1 Many herpes viruses probably recog-
nize multiple entry receptors, any one of which may be
sufficient for viral entry. Several drugs are known to
exhibit anti-herpes virus activity during viral replication
and show significant resistance to herpes viruses activity
with novel molecular mechanisms by targeting attach-
ment and entry (e.g., by heparin), virion fusion (e.g., by
Roscovitine).8 These examples support the hypothesis
that inhibitors that target and disrupt the lipid interfaces
mediating viral entry can be developed as broad-
spectrum antivirals.9
In previous studies, antiviral strategies have been tar-
geted at inhibiting or killing the herpes virus based on the
expression of vGPCR. A peptide (sequences NAHCALL,
known as H22-LP), based on the broad-spectrum chemokine
binding activity of US28, was designed to act as an analo-
gous site of vGPCR of the herpes virus, which was selected
from the N-terminal active site and the transmembrane
domain of US28 (H22), referred to as the trapping recep-
tor.10,11 In this report, we present the discovery of the H22-
LP antiviral that shows activity against HCMV.Methods
Cells and viruses
Human embryonic lung fibroblast (HELF) cells were grown in
Dulbecco’s Modified Eagle’s Medium supplemented with
10% fetal bovine serum (FBS). The Towne strain of HCMV
containing the green fluorescent protein (GFP) expression
cassette was propagated in HELF cells. The 50% tissue cul-
ture infectious dose (TCID50) measurements were done in
triplicates using eight serial four-fold dilutions of each
HCMV. For each dilution, 100 mL of diluted HCMV was added
to every well of a 96-well culture plate and then trypsinized
HELF cells were added. Plates were incubated at 37C, 5%
CO2 for 48 hours. An endpoint virus titer of TCID50 was
calculated by the Spearman-Karber method.12 TCID50 was
104.67/100 mL for HCMV.
Cytotoxic assay
The cytotoxicity of H22-LP was determined by the MTT
method. Briefly, HELF cells were incubated in 96-well
plates. After a period of incubation, MTT solution was
added to each well. Subsequently, cells were incubated for
4 hours at 37C then DMSO was added to each well. Samples
were measured at 590 nm in a microplate reader.
Antiviral effect assay of H22-LP against HCMV
To test the antiviral effect of H22-LP against HCMV, a strain
of virus containing green fluorescent protein (GFP) was
used.13 Briefly, HFLF cells (3.5  105 cells/well) were
seeded in 24-well plates 24 hours prior to infection. HELF
cells were washed with 1 DPBS and then treated with
mixture of 200 TCID50 of Towne-GFP strain of HCMV (20 mL/
well) and H22-LP (100 mL/well) in 24-well plates, which was
immediately added to the mixture without incubation. The
total volume was 200 mL/well. After infection, the virus was
removed and Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), penicillin
G (100 U/mL), streptomycin (100 mg/mL), and GlutaMAX
(2 mM) were added to each well and cells were incubated at
37C for 48 hours. GFP-positive cells were visualized 48
hours postinfection by fluorescence microscopy and then
quantified using flow cytometry.
Quantitative real-time PCR
H22-LP-treated and GCV-treated groups were prepared as
follows. HFLF cells (1 106 cells/well) were seeded in 24-
well plates 24 hours prior to infection. HELF cells were
washed with 1 DPBS and then treated with mixture of 200
TCID50 of Towne-GFP strain of HCMV (20 mL/well) and H22-
LP (100 mL/well), which was immediately added to the
mixture without incubation. The cells were treated with
the indicated concentrations ranging from 5 ng to 25 ng of
H22-LP for 7 days, 9 days, and 11 days (4 days following the
end of exposure to the drug) after infection and were
harvested for reverse transcription-polymerase chain re-
action (RT-PCR) analysis. In a further trial, the cells were
Peptide H22-LP 191treated with concentrations ranging from 50 mm to 150 mm
of GCV in the same conditions after infection.14e16
To analyze the viral RNA synthesis, a quantitative real-time
RT-PCR (qRTPCR) was conducted to determine the expression
level of the HCMV UL83 gene. Total RNA was prepared using
TRizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse
transcription was performed as follows: 11.5 mL total RNA and
2 mL Oligo(dT)15 were added to the tube. The mixture was
heated to 70C for 5 minutes and immediately transferred to
an ice bath for 5 minutes. Thereafter, 4 mL 5 RT reaction
buffer, 0.5 mL 400 U/mL RNase inhibitor, and 1 mL Moloney
murine leukemia virus reverse transcriptase (M-MLV) were
added. The tubes were incubated at 42C for 60 minutes and
95C for 10minutes. Primers andprobesweredesigned for the
UL83 gene of HCMVusing Primer Express (Applied Biosystems,
Foster City, CA, USA); forward primer (5-GTC
AGCGTTCGTGTTTCCCA-3), reverse primer (GGGACACAACA
CCGTAAAGC), and probe (CCGGCCCTCGGTTCTCTGCTG).
Primers weremanufactured by Qiagen (Qiagen, Valencia, CA,
USA), and FAM/TAMRA-labeled probes by Biosearch Technol-
ogies (Novato, CA, USA). RT-PCR was performed on the ABI
7300 Sequence Detection System using the SYBR Green Kit
(Invitrogen)under the followingconditions: 2minutesat50C,
3 minutes at 95C, followed by 10 cycles of 45 seconds at 95C
and 55 seconds at 60C. After completion of the PCR amplifi-
cation, the relative fold change was calculated based on the
2DDCt method17 (where Ct is cycle threshold).Western blot
HFLF cells (1  105 cells/well) were seeded in a 24-well
plate 24 hours prior to infection. HELF cells were washed
with 1 DPBS and then treated with a mixture of 200 TCID50
of Towne-GFP strain of HCMV (20 mL/well) and H22-LP
(100 mL/well), which was immediately added to the
mixture without incubation. The cells were treated with
the indicated concentrations ranging from 5 ng to 25 ng of
H22-LP for 7 days after infection and were harvested for
Western blotting analysis with the antibody against the late
protein (p65). In a further trial, the cells were treated with
concentrations ranging from 50 mm to 150 mm of GCV in the
same conditions following infection.
Cell samples were lysed in a radio-immunoprecipitation
assay buffer, and proteins were measured by the Bradford
assay. Cultures of the fibroblasts were harvested forWestern
blot analysis using a Laemmli sample buffer (Bio-Rad Labo-
ratories, Hercules, CA,USA). Cell lysatesweremixedwith 2
sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis (PAGE) loading buffer [125 mM Tris (pH 7.0), 20%
glycerol, 10% -mercaptoethanol, 6% SDS, and 0.2% bromo-
phenol blue], boiled for 5 minutes, and were then separated
by PAGE on 12% acrylamide gels. After blotting on poly-
vinylidene difluoride (PVDF) membranes (Bio-Rad Labora-
tories) and blocking for 2 hours with 5% nonfat dry milk in
10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% (w/v) Tween20, the
membranes were probed with one of the following primary
antibodies: anti-p65 antibody (1:1000 dilution, Santa Cruz,
Santa Cruz Biotechnology, CA, USA), anti-b-actin antibody
(Millipore, Bedford, MA, USA). Secondary antibodies used
included goat anti-mouse or -rabbit horseradish peroxidase-
conjugated (SouthernBiotech, Birmingham, AL, USA).Antibody-tagged protein bands on the probed membranes
were detected using diaminobenzidine peroxidase substrate
kit (Vector, Burlingame, CA, USA).18
Action mode of the peptides to HCMV
To determine the possible inactivated mechanism of H22-
LP, a series of experiments containing four different
treatment groups were designed for comparison with the
antiviral effect as follows. (1) H22-LP pretreated group.
HELF cells (3.5  105 cells/well) were pretreated with H22-
LP (10 ng/mL; 100 mL/well) at 37C for 120 minutes in 24-
well plates and then 200 TCID50 of HCMV (20 mL/well)
were incubated. The total volume was 200 mL/well. (2)
Infection first group. HELF cells (3.5  105 cells/well) were
infected with HCMV (20 mL/well) at 37C for 120 minutes in
24-well plates and then the infected cells were treated
with H22-LP (100 mL/well). The total volume was 200 mL/
well. (3) H22-LPþHCMV mixture group. HELF cells
(3.5  105 cells/well) were treated with a mixture of HCMV
(20 mL/well) and H22-LP (100 mL/well) in 24-well plates,
which was immediately added to the mixture without in-
cubation. The total volume was 200 mL/well. (4) H22-
LPþHCMV preincubation group. HCMV (20 mL/well) and
H22-LP (100 mL/well) preincubated at 37C for 120 minutes,
then the mixture was added to the HELF cells (3.5  105
cells/well) in 24-well plates.19 Cells were measured by GFP
assay after 48 hours incubation, as described above, and
the inhibitory rate was quantified.
Next, to determine the interaction time of the infection,
three other treatment groups were designed for compari-
son with the antiviral effect as follows. (1) Post group. HELF
cells (3.5  105 cells/well) were incubated with HCMV
(20 mL/well) for 120 minutes, then H22-LP (100 mL/well)
was added immediately after the adsorption phase of the
virus. (2) Pre-post, HELF cells (3.5  105 cells/well) were
treated with a mixture of HCMV (20 mL/well) and H22-LP
(100 mL/well) in 24-well plates, but which was immedi-
ately added to the mixture without incubation. (3) Pre
group, HELF cells (3.5  105 cells/well) were pretreated
with the mixture of H22-LP (100 mL/well) and HCMV (20 mL/
well) at 37C for 120 minutes, during which H22-LP was
exclusively preincubated on cells and removed after virus
adsorption.20 Cells were measured by GFP assay following
48 hours of incubation, as described above, and the inhib-
itory rate was quantified.
Statistical analysis
Data were presented as mean  SD (standard deviation).
Multiple comparisons were statistically analyzed using SAS
software (statistica analysis system, SAS Institute INC., NC,
USA) version 8.0. Significant differences (p < 0.05) between
groups were determined using unpaired Student t test.
Results
H22-LP acted sensitively and rapidly against HCMV
To confirm whether anti-HCMV activity of H22-LP was
dependent on dose, several doses of H22-LP anti-HCMV
192 W. Shi et al.activity were measured according to the number of GFP
positive cells. The cytotoxic assay has been described by
Liu et al.11 As shown in Fig. 1A, the antiviral-activity of H22-
LP against HCMV was dose-dependent and an inhibition of
50% was achieved at a concentration of 5 ng/mL. Up to
85.15% inhibition was achieved when the concentration
rose to 50 ng/mL. To determine the effective time needed
for H22-LP to act on HCMV, 10 ng/mL H22-LP was incubated
with 200 TCID50 of HCMV for 10 minutes, 30 minutes, 60
minutes, 120 minutes and 240 minutes, respectively. As
shown in Fig. 1B, with increasing time, higher inhibition was
observed. However, there was no significant difference
between the 120 minute treatment group and the 240
minute treatment group. Yet, inhibition was as high as
47.5% for the 10 minute treatment group. Therefore, the
time taken for H22-LP to act on HCMV is extremely short
with activity eventually peaking at 120 minutes. These re-
sults show that the anti-HCMV activity of H22-LP is rapid.Inhibition of HCMV replication and cellular gene
expression
After treatment with H22-LP, HELF cells were harvested for
RT-PCR (Fig. 2A) and Western blot analysis (Fig. 2B). The
levels of HCMV DNA were measured for the control group,
GCV group, and H22-LP group, respectively. After treat-
ment, the levels of HCMV DNA decreased with elevation of
H22-LP compared to the control group in a concentrationFigure 1. Dose- and time-dependent effects of H22-LP
against human cytomegalovirus (HCMV). (A) Dose-dependent
effect of H22-LP. *p < 0.05 versus the corresponding HCMV
group and (B) time-dependent effect of H22-LP.dependent manner (p < 0.05). As shown in Fig. 2A, the
inhibition effect of H22 LP-treated cultures reached a peak
value of 88.3% at 25 ng on Day 9 and kept to approximately
54% at Day 11 (4 days after the end of exposure to the
drug). Interestingly, the inhibition rates of H22-LP on HCMV
DNA at Day 11were lower than those observed on Day 9.
However, they were higher than those on Day 7. At the
same time, the inhibition values of GCV for HCMV RNA
declined and were lower than the values on Day 7. Next, to
determine if the decrease in protein expression was regu-
lated at the protein level, we examined the changes in
steady-state late protein (p65) levels by Western blot
analysis. As shown in Fig. 2B, the levels of protein were
reduced with elevation in H22-LP and GCV concentrations.
The levels of protein expression in H22-LP treatment groups
were higher than the levels of protein expression in GCV
treatment groups at Day 7. The antiviral effect analyzed by
Western blot was consistent with the antiviral effect
analyzed by RT-PCR at Day 7. These results indicate that
the anti-HCMV protein activity of H22-LP is concentration-
dependent and may have a persistent effect on suppress-
ing HCMV.
Characterization of H22LP-mediated inhibition of
HCMV replication
HELF cells were varied in seven different groups as
described in the Methods section. As shown in Fig. 3A, H22-
LP (10 ng/mL) incubation of HCMV for 120 minutes prior to
inoculation of HELF cells (H22-LPþHCMV preincubation
group) showed a prominent inhibitory effect. A mixture of
HCMV and H22-LP (10 ng/mL), which were not preincubated
(H22-LPþHCMV), also showed significant inhibition.
Because of the same treatment conditions, a similar anti-
viral effect of H22-LP (10 ng/mL) was demonstrated
(Fig. 1A). However, the pretreated group and infection first
group did not show significant antiviral effect (Fig. 3A).
Importantly, the pre-group, in which H22-LP (10 ng/mL)
was exclusively preincubated on cells and removed after
the virus adsorption, and the pre-post group, in which H22-
LP (10 ng/mL) was pretreated with HCMV prior to inocula-
tion, were both essential to obtain the antiviral effect.
However, no significant difference was observed in the post
group when H22-LP (10 ng/mL) was added to the mixture of
HCMV and cells following virus adsorption. By contrast,
when GCV was exclusively preincubated on cells and
removed after virus pre-adsorption, no inhibition was
observed (Fig. 3B). The results of these treatments using
H22-LP (10 ng/mL) indicates that HCMV cell adsorption/
entry is inhibited by H22-LP.
Discussion
Currently, nucleoside analogs play an important role in the
therapy of HCMV. However, some disadvantages of these
agents include side effects, drug resistance, and expense,
which limit their clinical use in HCMV-infected patients.
However, an important factor to be taken into account
when considering anti-virus therapies is that H22-LP, as a
small molecule peptide, binds to virus encoded chemokine
receptors but does not initiate cytoplasmic signal
Figure 2. The inhibitor effect on the levels of mRNA and
proteins in GCV groups and H22-LP groups at different con-
centrations. (A) The inhibitor effect on the levels of mRNA. (B)
The inhibitor effect on the levels of proteins. b-Actin was used
as the internal reference. Lane 1: negative control; lane 2:
H22-LP (5 ng); lane 3: H22-LP (10 ng); lane 4: H22-LP (25 ng);
lane 5: GCV (50 mM); lane 6: GCV (100 mM); and lane7: GCV
(150 mM). *p < 0.05 versus the corresponding negative control.
**p < 0.05 versus the corresponding 7 days outcome of the
same dose. ***p < 0.05 versus the corresponding 11 days
outcome of the same dose.
Figure 3. The mechanism of H22-LP against HCMV. (A) (i)
H22-LP pretreated group: HELF cells were pretreated with
10 ng/mL H22-LP at 37C for 120 minutes prior to infection; (ii)
infection first group: HELF cells were infected with HCMV at
37C for 120 minutes and then treated with 10 ng/mL H22-LP;
(iii) H22-LPþHCMV mixture group: HELF cells were treated with
mixture, without incubation, of HCMV and 10 ng/mL H22-LP;
(iv) H22-LPþHCMV preincubation group: HCMV and 10 ng/mL
peptides preincubated at 37C for 120 minutes, then the
mixture was added to the HELF cells. H22-LP directly targeted
HCMV. (B) H22-LP inhibits HCMV cell adsorption/entry. (i) Post
group: HELF cells were incubated with HCMV for 120 minutes,
then 10 ng/mL H22-LP was immediately added after the
adsorption phase of the virus; (ii) pre-post group: HELF cells
were pretreated with 10 ng/mL H22-LP at 37C prior to infec-
tion; (iii) Pre group: HELF cells were pretreated with the
mixture of H22-LP and HCMV at 37C for 120 minutes, when
H22-LP was exclusively preincubated on cells and removed
after virus adsorption. *p < 0.05 versus the GCV groups.
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kine, which initiates a series of signal cascades by binding
to receptors, can therefore be considered as a candidate
site of antagonists. Besides CCR5 and CXCR4, several che-
mokine receptors and related orphan GCRs have been found
to mediate CD4-dependent HCMV entry, with various effi-
cacies.21,22 US28 can also enhance cellecell fusion by a
mechanism apparently distinct from HIV coreceptor activ-
ity. Thus, a small molecule peptide H22-LP was designed,
which derived from the US28 N-terminal region of
HCMV.10,11
Many parts of the chemokine system have been hijacked
and wrecked by herpes viruses, including the ligands and
the receptors. A great number of chemokine receptor an-
tagonists have been applied to animal experiments and
clinical studies in recent years.23 In a previous study, H22-
LP was found to bind to the US28 receptor on NIH/3T3
cells, with an emphasis on H22-LP being an effective
antagonist for US28. This agrees with previous findings that
CC chemokines can increase the intracellular concentration
of Ca2þ.10,11
In this study, we examined the activities of H22-LP
against HCMV in vitro and the possible antiviral mechanismusing the Towne strain of HCMV, which proved to be useful
and reliable for the determination of the HCMV lytic
replication. The experimental results showed H22-LP pro-
vided significant inhibitory effects to HCMV. The activity of
H22-LP against HCMV was dose dependent with an inhibi-
tion rate of 50% achieved at a concentration of 5 ng/mL.
Compared with the 10 minute treatment group and 60
minute treatment group, no significant difference was
observed between the 120 minute treatment group and 240
minute treatment group. The results show that the anti-
194 W. Shi et al.HCMV activity of H22-LP is rapid and the possible antiviral
mechanism is similar to that of mucroporin, which is a host
defense peptide of bacteria. Interaction time between
adsorption and membrane fusion continues to be a current
focus of research.24
Herpes viruses engage multiple receptors during viral
entry. Inhibition of the target and disruption of the lipid
interfaces mediating virusecell fusion could be developed
as broad spectrum antivirals. As reported earlier, lyso-
phosphatidylcholine can stabilize positive spontaneous
curvature of membranes and prevent entry of several vi-
ruses25. We assumed that H22-LP may implement the inhi-
bition of HCMV using a similar mechanism. Research using
four different treatment groups employing H22-LP to HCMV,
in which viral infectivity was inhibited only when H22-LP
was able to interact directly with HCMV, provided us with
a clue indicating H22-LP may exert its antiviral activity by
damaging the HCMV virus particle itself. We, therefore, set
up three different treatment groups using H22-LP to test
this assumption. When H22-LP and GCV were added to the
infected cells after the adsorption phase (post group), the
antiviral effect of H22-LP was lower than the antiviral ef-
fect of GCV. As a nucleoside analog that is activated by
phosphorylation, GCV can inhibit the integration of dGTP by
viral DNA polymerase, resulting in the termination of the
elongation of viral DNA.7 Thus, although H22-LP and GCV
were removed following virus adsorption (pre group), the
inhibition values of H22-LP remained around 41.3%, which
was higher than the inhibition values of GCV. The results
show that the time needed for H22-LP to act on HCMV is
short and HCMV cell adsorption/entry is inhibited by H22-
LP. In the experiments examining the effective action
time of H22-LP on HCMV, it was observed that 10 minutes of
interaction allowed H22-LP to show almost maximum inhi-
bition of HCMV (Fig. 2B). We may deduce the active prin-
ciples as follows: once H22-LP encounters HCMV, H22-LP
binds to US28 of HCMV directly and immediately. The
attached H22-LP aggregates and inserts into viral entry
receptors so that US28 is unable to bind with other re-
ceptors, which then inhibits the triggering events for viral
entry. In summary, we have described a small molecule
inhibitor that prevents enveloped virus entry. However,
further research will be required to clarify our findings with
regard to whether H22-LP can inhibit virus entry between
virus binding and virusecell fusion.
These results demonstrate that H22-LP exhibited resis-
tance to HCMV in vitro and could inhibit HCMV by direct
interaction with the viral particle.Conflicts of interest
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